Pfizer, Inc. (PFE) Financials
PFE Assets vs Liabilities
| Date | Assets | Liabilities |
|---|---|---|
| 2023-12-31 | 226.5 billion | 137.2 billion |
| 2023-09-30 | 215.0 billion | 117.8 billion |
| 2023-06-30 | 220.2 billion | 120.9 billion |
| 2023-03-31 | 195.6 billion | 94.4 billion |
PFE Free Cash Flow and Stock based compensation
| Date | Free Cash Flow | Stock based compensation |
|---|---|---|
| 2023-12-31 | 4.2 billion | 121.0 million |
| 2023-09-30 | 2.6 billion | 151.0 million |
| 2023-06-30 | -2.1 billion | 148.0 million |
| 2023-03-31 | 73.0 million | 105.0 million |
PFE Net Income
| Date | Net Income |
|---|---|
| 2023-12-31 | -3.3 billion |
| 2023-09-30 | -2.4 billion |
| 2023-06-30 | 2.3 billion |
| 2023-03-31 | 5.6 billion |
PFE Cash and Debt
| Date | Cash | Debt | Capital Lease |
|---|---|---|---|
| 2023-12-31 | 12.7 billion | - | - |
| 2023-09-30 | 44.2 billion | 61.0 billion | - |
| 2023-06-30 | 44.8 billion | 61.4 billion | - |
| 2023-03-31 | 20.0 billion | 31.7 billion | - |
PFE Shares Outstanding
PFE Expenses
| Date | Capex | R&D | G&A | S&M |
|---|---|---|---|---|
| 2023-12-31 | 1.0 billion | 2.8 billion | 4.6 billion | - |
| 2023-09-30 | 810.0 million | 2.7 billion | 3.4 billion | - |
| 2023-06-30 | 914.0 million | 2.6 billion | 3.5 billion | - |
| 2023-03-31 | 1.1 billion | 2.5 billion | 3.5 billion | - |
PFE Cost of Revenue
| Date | Revenue | Cost of Revenue |
|---|---|---|
| 2023-12-31 | 14.2 billion | 8.6 billion |
| 2023-09-30 | 13.2 billion | 10.6 billion |
| 2023-06-30 | 12.7 billion | 3.2 billion |
| 2023-03-31 | 18.3 billion | 6.0 billion |
PFE
List: Contenders
Price: $25.39
Dividend Yield: 0.06%
Forward Dividend Yield: 6.62%
Payout Ratio: 454.05%
Dividend Per Share: 1.68 USD
Earnings Per Share: 0.37 USD
P/E Ratio: 72.78
Exchange: NYQ
Sector: Healthcare
Industry: Drug Manufacturers - General
Volume: 23.8 million
Ebitda: 3.6 billionMarket Capitalization: 149.0 billion
Average Dividend Frequency: 4
Years Paying Dividends: 53
DGR3: 5.15%
DGR5: 6.95%
DGR10: 6.50%
DGR20: 8.23%